Wexford Capital’s Merck MRK Stock Holding History

Wexford Capital’s Portfolio MRK Stock Details MRK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-7,667	Closed	-$949K	–	208
2024 Q2	$949K	Sell	7,667 -41,135	-84%	-$5.3M	0.24%	69
2024 Q1	$6.44M	Buy	48,802 +10,562	+28%	+$1.3M	1.32%	20
2023 Q4	$4.17M	Buy	38,240 +8,578	+29%	+$890K	0.89%	36
2023 Q3	$3.05M	Buy	29,662 +27,896	+1,580%	+$3.01M	0.68%	35
2023 Q2	$204K	Sell	1,766 -34,101	-95%	-$3.87M	0.04%	181
2023 Q1	$3.82M	Buy	+35,867	New	+$3.87M	0.79%	32

Other funds holding MRK

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wexford Capital's MRK Position: Q3 2024 in Review

Wexford Capital sold out of Merck (MRK) in Q3 2024, closing a stake of 7,667 shares — an estimated $949K sold.

Wexford Capital first reported a position in MRK in Q1 2023 and held it in 6 quarters. The position peaked at $6.44M in Q1 2024. 3,489 funds tracked by Wall St. Rank hold MRK as of Q3 2024.

Wexford Capital reported no remaining Merck position as of Q3 2024 after selling out during the quarter.
Wexford Capital sold 7,667 Merck shares in Q3 2024, an estimated $949K.
Wexford Capital first reported a position in Merck in Q1 2023 and held it in 6 quarters.
Wexford Capital's Merck position peaked at $6.44M in Q1 2024.
3,489 funds tracked by Wall St. Rank held Merck as of Q3 2024.

Based on Wexford Capital's 13F filing for Q3 2024, filed 14 Nov 2024.